Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Stock Information for Atossa Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.